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A select group of patients with upper tract urothelial carcinoma may be appropriate candidates for minimally invasive
management. Organ-preservingendoscopic procedures maybeappropriate for patients with an inability totolerate major surgery,
solitary kidney, bilateral disease, poor renal function, small tumor burden, low-grade disease, or carcinoma in situ. We review the
published literature on the use of topical treatment for upper tract urothelial carcinoma and provide our approach to treatment in
the oﬃce setting.
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1.Introduction
Nephroureterectomy with open excision of bladder cuﬀ
remains the standard of care for organ-conﬁned upper tract
urothelial cancer in patients with a normal contralateral
kidney. Laparoscopic surgery has broadened the population
of patients who are able to tolerate this surgery;however, due
to concerns for preservation of renal function or inability to
tolerate surgery, a selected group of patients may be suitable
candidates for less-invasive management with endoscopic
approach. Organ-preserving endoscopic procedures may be
appropriate for patients with a solitary kidney, bilateral
disease, poor renal function, or inability to tolerate major
surgery [1, 2]. In addition, the indications for minimally
invasivetherapyhaveevolvedtoincludesmalltumorburden,
low-grade disease, or carcinoma in situ in patients with
normal contralateral renal function [3]. Patients with high-
grade disease, multifocal tumors, or history of recurrent
tumor are not ideal candidates for topical therapy because
of risk of recurrent or progressive disease. Patients managed
with less invasive treatment must be made aware of the
concern for progressive or recurrent disease. In addition,
patients must be compliant with both the treatment regimen
and the required subsequent follow-up.
The role of intravesical immunotherapy in non-muscle-
invasive urothelial cancer of the bladder has been ﬁrmly
established [4, 5]. A variety of agents have been utilized
(Table 1), with BCG showing the greatest eﬃcacy [4]. In the
treatment of upper tract urothelial carcinoma, instillation
of topical immunotherapy has been used as primary or
adjuvant treatment, but upper tract treatment can be
problematic because agents must be delivered to the renal
pelvis and ureter to be eﬀective. A challenge to the practicing
urologist is ﬁnding a way to implement this treatment in
the busy oﬃce setting. We review the published literature
on topical treatment of upper tract urothelial cancer, and
provide our approach to treatment in the oﬃce setting.
2. Upper Tract Evaluation
Patients must be properly selected for topical upper tract
treatment. Upper tract abnormalities are often identiﬁed
as a ﬁlling defect on delayed images of a CT urogram
or IVP done for hematuria work-up or during selective
upper tract washings for a positive bladder cytology in the
absence of any bladder pathology. Our operative evaluation
for positive cytology includes evaluation of both the bladder
and upper tract for source of positive cytology. Initially, a
rigid cystoscope is introduced and the bladder is inspected.
The bladder is drained and a bladder wash with normal
saline is obtained for cytology by rinsing the bladder several
times. Cytology from the ﬁrst kidney is obtained using
normalsalinewashesthrougha5frenchopen-endedureteral
catheter. To reduce the chance of bladder contamination,
positive pressure saline is infused through the catheter up2 Advances in Urology
Table 1: Mechanism of immunotherapy agents.
BCG Inﬂammatory host response
Release of cytokines
Interferon
Lymphocyte activation
Cytokine release
Phagocyte stimulation
Antiproliferative actions
Antiangiogenic
Thiotepa Alkylating agent
Crosslinks nucleic acids
Mitomycin C Inhibits DNA synthesis
Gemcitabine Deoxyctidine analog
Inhibits DNA synthesis
until the point in which it is introduced into the ureter
The catheter is advanced up into the renal pelvis (∼25cm)
and two 5–7cc saline washes are obtained followed by
additional washes at 20, 15, and 10cm. The catheter is then
readvanced up into the renal pelvis where the remaining
ﬂuid is aspirated and pooled together with the other washes.
A retrograde pyelogram is then performed from the renal
pelvis downwards as the catheter is removed. The same
procedure is then performed on the contralateral upper
tract. It should be noted that special care must be taken
to avoid contamination of specimens by using diﬀerent
ureteral catheters for each side. If any abnormality is seen
on retrograde pyelogram, then the upper tract should be
evaluated with ureteroscopy with subsequent upper tract
wash, brush biopsy, or tissue biopsy as deemed appropriate.
The bladder should be inspected and ﬁve random bladder
biopsies taken in a stellate manner (trigone, base, dome,
and both lateral side walls). An essential component of a
complete evaluation is to obtain a separately labeled biopsy
fromtheprostaticurethra,whichcanserveasasanctuarysite
for urothelial carcinoma.
Patients treated with topical infusion therapy typically
have either carcinoma in situ or lesions that have been
resected endoscopically. A mass in the collecting system or
ureter identiﬁed on retrograde pyelogram or CT urogram
prompts a focused operative evaluation. Small lesions may
be amenable to endoscopic treatment (ureteroscopic or
percutaneous) as discussed elsewhere in this special issue.
It is highly unlikely that topical treatment by itself would
eradicate radiographically visible disease. After primary
treatment or the presence of hematuria, BCG treatment
should be delayed 2 to 4 weeks to allow the urothelium
to heal and decrease the likelihood of systemic side eﬀects.
Of note, in patients with positive cytology from both the
bladder and upper tract with no mass lesion, the status of the
uppertractshouldbeconsideredinconclusive.Inthesecases,
we generally start with intravesical treatment as the positive
upper tract cytology could be due to contamination from
the bladder. Restaging after intravesical therapy is prudent
to reevaluate the upper tracts. If the bladder is disease-free
and the upper tract cytology continues to be positive, then
Figure 1
this rules out the possibility of contamination and should be
treated accordingly.
3. Ofﬁce-Based Approachfor
Upper Tract Treatment
We use an oﬃce-based approach for placement of ureteral
catheter(s) for upper tract therapy. Flexible cystoscopy is
performed, sometimes with oral narcotic/benzodiazapine
premedication or intravenous sedation (morphine, versed)
based on patient preference. The ureteral oriﬁce is visualized
and cannulated with a 0.018 inch angled glidewire that is
passed to the renal pelvis. A 4F whistle-tip catheter is then
passed over the glidewire (Figure 1). Under direct vision, the
catheter is slid over the wire into the ureter and a second
ureteral catheter with the tip cut oﬀ is used as a pusher to
further advance the catheter. Using the catheter markings
as a guide, the catheter is typically advanced to 25cm to
place it in the renal pelvis. The ﬂexible scope is then carefully
backed out leaving the catheter in the mid renal pelvis. The
guidewire is subsequently removed once proper positioning
is established. It is very helpful to use ﬂuoroscopy, at least for
theﬁrstsession,toestablishpropercatheterpositionandrule
out unexpected anatomical diﬃculties. Free ﬂow of urine
from the catheter or retrograde injection of contrast veriﬁes
proper position in the collecting system. Ureteral catheters
are secured via silk ties to a foley catheter placed to drain the
b l a d d e ra n db r o u g h tt or e s ta tt h eb l a d d e rn e c k( Figure 2).
The Foley catheter is either left to straight drainage or
elevated over the bedrail to allow some collection into
the bladder depending on whether simultaneous bladder
exposureisdesired.Itmayalsobecappedduringtreatmentif
formalintravesicalinstillationisperformedatthesametime.
This particular technique of using a small caliber ureteral
catheter over a small slippery wire is usually very atraumatic
and allows free ﬂuid ﬂow around and out the splinted
ureter. If trauma or bleeding is encountered, then treatment
may need to be deferred in the case of BCG. In patients
who have previously undergone cystectomy with urinary
diversion, treatment is usually performed with percutaneous
nephrostomy tube as retrograde access to the ureter is
diﬃcult.
We use a treatment regimen of low-dose BCG (one-
third to one-tenth standard dose) plus interferon-alpha-2bAdvances in Urology 3
Figure 2
(50–100 million units) in 50cc normal saline based on
the eﬀectiveness of this combination in non-muscle-invasive
bladder cancer [5]. The viscosity of the full-dose BCG
suspension is such that it will not spontaneously drip
under gravity instillation through such a small 4 french
catheter. The patient is positioned supine. The medication
is suspended in an IV bag no more than 30cm above the
kidney level. Medication is instilled via microdrip tubing at
the rate of 1 drop per 2 seconds, corresponding to a rate of
approximately30cc/h.Medicationisonlyinstilledviagravity
and should never be placed on a pump due to concern for
increasedintrarenalpressure.Attheconclusionoftreatment,
the foley catheter is drained and then removed, bringing
the attached ureteral catheters out with it. If treatments
are not able to be administered via ureteral catheters, then
a percutaneous nephrostomy tube can be placed at the
beginning of treatment and medicine can be instilled via
nephrostomy tube, with the tube capped between weekly
treatments.
Patients receive weekly treatment for 6 sessions over 6
weeks. Then, 6 weeks following the last treatment, patients
are restaged with bilateral upper tract washings and retro-
grade pyelograms, bladder washing, and random bladder
biopsies along with prostatic urethral biopsy. If the results
are negative, consideration is given to 3 future maintenance
treatments starting 6 weeks later. While there have been no
published results on the eﬃcacy of maintenance treatment,
the addition of 3 weekly maintenance treatments is well
established for bladder CIS [6].
4. LiteratureReview
The true beneﬁt of topical therapy, either as a primary
treatment for carcinoma in situ or as an adjuvant for
endoscopically treated tumors, is diﬃcult to assess based on
the variance in the reported literature. In contrast to bladder
cancer, which is relatively common, upper tract urothelial
cancerisuncommonand,therefore,asinglecenterisnotable
to accrue signiﬁcant numbers of patients for a prospective
study. Additionally, heterogeneous groups of patients receive
such therapy (solitary versus multifocal disease, primary
versus recurrent, low- versus high-grade). Retrospective case
reviews can also have methodological ﬂaws. The goal is to
maximize the eﬀectiveness of treatment while minimizing
side eﬀects and complications. Multiple diﬀerent treatment
regimens have been utilized with BCG being used most
commonly (Table 2). No randomized studies have been
performed to evaluate such therapy, and most studies
have set the number of instillations empirically based on
expert opinion or extrapolating from intravesical treatment
regimens.
5. BCG
In 1996, Yokogi et al. analyzed therapeutic outcomes of
BCG perfusion therapy for upper urinary tract CIS in 8
renal units—5 through a percutaneous nephrostomy tube
and 3 through a retrograde ureteral catheter [7]. Follow-
up cystoscopy, retrograde pyelography, and selective urinary
cytology were obtained 4 weeks after the last treatment and
every 3 months thereafter. In 5 of 8 renal units, the cytology
remained negative for 10 to 46 months after treatment, while
the other 3 renal units had persistently positive cytology. Of
2 patients treated through a ureteral catheter, 1 developed a
ureteral stricture and the other developed renal tuberculosis,
which emphasizes that urologists must be mindful of the
development of complications.
In contrast, Nishino et al. used BCG perfusion treat-
ment (instilled weekly for 4 or 8 weeks) to treat upper
tract CIS via retrograde catheterization with either a 6
French ureteral catheter or an 8 French indwelling double
J ureteral stent [8]. At a mean follow-up of 22 months
(range 9–38 months), all 8 renal units had negative cytol-
ogy, and cytology became negative after 1 or 2 instil-
lations of BCG. However, 1 patient had recurrent CIS
in the prostatic urethra treated with intravesical BCG
instillation. Complications included ureteral stenosis in 2
patients and self-limited irritative symptoms occurred in all
patients.
An indwelling ureteral stent was used to treat 11 patients
with upper tract CIS as reported by Nonomura et al. in
2000 [9]. Reﬂux up the ureteral stent was conﬁrmed using
contrast at the time of initial ureteral stent placement. BCG
was instilled into the bladder weekly, 6 times in total as
1 course. At the end of 1 course, 9 cases showed negative
urinary cytology; however, 2 patients had recurrence in the
upper urinary tract after 4 and 8 months, and repeat BCG
therapy was not eﬀective. Two patients never normalized
their cytology. The mean recurrence-free time was 19.6
months. As side eﬀects, 8 cases (72.7%) developed bladder
symptoms, and 4 presented with fever higher than 38◦C, but
the authors reported that no patient needed antitubercular
treatment.
The eﬃcacy of retrograde ﬂow to the upper tract via
an indwelling double J ureteral stent has been questioned.
Yossepowitch et al. used performed cystograms with an
indwelling stent in place and reported that retrograde ﬂow
occurred in only 56% of patients. Additionally, the mean
minimal intravesical volume to obtain reﬂux was 170mL,
which is higher than the typically instilled treatment volume
[10].4 Advances in Urology
Table 2: Topical therapy of upper tract urothelial cancer.
Study Indication No. patients/no. renal units Therapy
Mean
follow-up,
months
Comments
Jarret et al. 199519
Adjuvant to
percutaneous
treatment
17 patients/19 renal units BCG 55
No signiﬁcant
improvement in survival
with BCG
Elliott et al. 199618 Adjuvant to
endoscopy
18 patients
BCG,
thiotepa,
MMC
NA
No diﬀerence in outcome
between treated and
untreated
Yokogi et al. 19967 CIS 5 patients/8 renal units BCG 10–46 NED in 5/8 renal units
Martinez-Pineiro et al. 199617 Adjuvant to
endoscopy
26 patients BCG, MMC,
thiotepa 31
12.5% recurrence with
BCG, 14% with MMC,
60% with thiotepa
Keeley and Bagley, 19971 Adjuvant to
ureteroscopy
19 patients/21 renal units MMC 30
35% complete response,
27% partial response, 38%
no response
Patel and Fuchs, 199812 Adjuvant to
ureteroscopy
13 patients/17 renal units BCG 15 NED in 15/17 renal units
Nishino et al. 20008 CIS 6 patients/8 renal units BCG 22 NED in 8/8 renal units
Nonomura et al. 20009 CIS 11 patients BCG NA NED in 7/11 patients
Burns et al. 200114 CIS, adjuvant
to endoscopy
15 patients/23 renal units BCG-IFN 15 70% response rate
Thalmann et al. 200213
Not eligible
for open
surgery
37 patients/41 renal units BCG 42
87% recurred or
progressed; 32% CIS were
disease-free
Miyake et al. 200211 CIS 15 patients/16 renal units BCG 30 NED in 14/16 renal units
Palou et al. 200420
Adjuvant to
percutaneous
treatment
19 patients BCG in 14,
MMC in 5 51
60% recurrence in treated
patients vs 27% in
untreated patients
Katz et al. 200716 CIS, adjuvant
to endoscopy
10 patients/11 renal units BCG-IFN 24 80% complete response,
20% partial response
∗BCG - bacillus Calmette-Guerin; MMC - mitomycin C; CIS - carcinoma in situ; IFN - interferon; NED - no evidence of disease; NA - not applicable.
Miyake et al. evaluated the eﬃcacy of intrarenal BCG
instillation for the treatment of CIS of the upper urinary
tract [11]. Sixteen patients (17 renal units) were treated
with BCG administered once weekly, 6 times in total
using percutaneous nephrostomy tube in 5 patients, and a
retrogradeureteralcatheterin11.Duringthemedianfollow-
upperiodof30months(range9–90months),13patients(14
renal units) remained cytologically negative. However, 1 of
these13patientshadCISinthebladderandprostaticurethra
34 months after the BCG therapy and underwent radical
cystectomy. Bladder irritability and fever higher than 38◦C
was observed in 12 and 9 patients, respectively; however, no
patient received antitubercular treatment.
In the adjuvant setting after ureteroscopic tumor abla-
tion, Patel and Fuchs in 1998 reported on the use of topical
BCG therapy (indwelling stent and intravesical BCG in 3
renal units, and ureteral catheter instillation passed through
a suprapubic stab incision in 14 which allowed the avoidance
of weekly cystoscopy) [12]. At a mean follow-up of 15
months, 15 of 17 renal units were preserved and remained
tumor-free. Patients in this series were followed with regular
ﬂexible ureteroscopy along with cytology washings in the
clinic using topical anesthesia. The authors attributed the
favorable outcome in preserving renal units to improved
resections made possible by the development of small caliber
ureteroscopes, improved optics, and new ablative energy
sources such as the holmium:YAG laser.
In one of the largest series of topical upper tract
treatment, Thalmann et al. (2002) retrospectively evaluated
the results of BCG therapy for upper urinary tract disease
in patients not eligible for nephroureterectomy [13]. Thirty-
seven patients (22 with CIS, 15 with Ta or higher after
endoscopic resection) were treated with 6 weekly perfusions
of BCG via a 10 French nephrostomy tube. At a median
follow-up of 42 months (range 8–137 months), 14 patients
(38%) died of urothelial cancer, 11 (29%) of other causes,
and 12 (33%) were alive. Other adverse outcomes included
severe septicemia in 2 patients. There was no seeding of the
nephrostomy tube tract and dialysis was avoided. Overall
median survival was 42 months (range 1–137 months) with
median recurrence-free survival of 21 months (range 1–
137 months). The authors noted that this was a patient
population with a poor prognosis and while BCG extended
survival for some patients, it did not provide cure except
for some patients with CIS. Of the patients treated in the
adjuvant setting for papillary disease, only 13% remainedAdvances in Urology 5
without recurrent or progressive disease with a median time
of recurrence of 10 months. In contrast, treatment of CIS
resulted in 32% of renal units remaining disease-free for a
median follow-up of 51 months.
6. BCG Plus Interferon
The data regarding supplemental interferon is not ﬁrmly
established, validated, or widely used for bladder cancer and
certainly not for upper tract transitional cell carcinoma.
However, there have been two reports of its use in treating
upper tract urothelial carcinoma. We have reported on 15
patients (23 renal units) with upper tract urothelial cancer
after endoscopic resection who received 6 weekly adjuvant
low-dose BCG (one-tenth standard dose) and interferon-
α (100 million units) [14, 15]. Nineteen of the renal units
h a dC I S ,2h a dT ag r a d e1 ,o n eh a dT ag r a d e3 ,a n do n e
had T1 grade 3. Sixteen were treated with ureteral catheters
while seven were treated with percutaneous nephrostomy
tubes. At a mean follow-up of 15.3 months (range 3–44
months), the response rate was 70% (16 of 23 renal units).
The highest response rate was in patients with CIS (14 of 19;
74%). One patient had BCG sepsis that required 6 months of
antitubercular therapy.
In 2007, Katz et al. published their initial experience
w i t hu p p e rt r a c tB C G - I F N[ 16]. A series of 10 patients (11
renal units) received 6 weekly courses of BCG (half strength)
plus IFN-α2b (50 million units) via ureteral catheter. With
a median follow-up of 24 months, 80% demonstrated
a complete response, while 20% had a partial response
(decrease in tumor size, number, or both). The authors
reported that the treatment was well tolerated in the oﬃce
setting and did not note any complications.
7. Other Agents
Less information is available on the use of mitomycin C
topical treatment. In 1997, Keeley and Bagley reported
on adjuvant mitomycin C (40mg in 3 divided doses via
ureteral catheter) in 19 patients (21 renal units) for high
volume, recurrent, or multifocal urothelial carcinoma [1].
No systemic side eﬀects occurred during or after treatment
with mitomycin C which was attributed to the high molec-
ular weight of mitomycin and limited systemic absorption.
Thirty-ﬁve percent had a complete response, 27% had a
partial response (reduction in tumor size > 50%), and 38%
had no response. Tumors with a complete response were
of similar size and grade as those that did not respond
as well. With a mean follow-up of 30 months, none of
the patients suﬀered local disease progression or died of
disease; however, nearly all of the patients required repeat
ureteroscopic treatment for residual or recurrent disease.
Due to confounding variables and heterogeneous treat-
ment groups, direct comparisons between treatment groups
in a study can be diﬃcult. One study in 1996 from Mart´ ınez-
Pi˜ neiro et al. reported on a series of upper tract carcinoma
in which 26 patients received adjuvant supplemental topical
therapy, and attempted to make comparisons between
diﬀerent treatments [17]. BCG and mitomycin C seemed to
be most eﬀective at preventing recurrences, with recurrence
rates of 12.5% and 14.2%, respectively, compared to 60%
for thiotepa. Fatal aplastic anemia from systemic absorption
of MMC was reported in 1 patient. In 1996, Elliott et
al. reported the Mayo Clinic experience with endoscopic
treatment of upper tract urothelial carcinoma in which 18 of
44 patients received some form of topical therapy (BCG in 9,
MMC in 5, thiotepa in 4) [18]. Their methods did not report
mode of delivery. In their sample, a diﬀerence was not found
in recurrence between those who did and did not receive
adjuvant topical therapy. Similarly, Jarrett et al. reported that
BCG therapy showed no signiﬁcant improvement in survival
in 19 of 30 renal units [19].
Similarly, comparisons between treatment and nontreat-
ment groups may be complicated by selection bias. In 2004,
Palou et al. presented results of the percutaneous approach
to resection of upper urinary tract urothelial carcinoma
in which 14 and 5 patients received BCG and MMC
instillations, respectively [20]. Median time to recurrence
was 24 months and the rate of kidney preservation was 74%.
The authors reported a recurrence rate of 58% in those
who received topical therapy compared to 27% in those who
did not; however, the topical therapy group was higher risk
with higher grade disease and comprised more patients with
multiple tumors. There was a trend of recurrence in patients
with multifocal tumors, history of bladder carcinoma in situ,
and tumor in renal pelvis. The authors concluded that the
percutaneous approach to renal urothelial tumor should be
considered a valid option with a good long-term outcome;
however, there was an obligation to a long-lasting, strict
surveillance.
An alternative experimental treatment regimen in refrac-
tory patients is sequential gemcitabine and mitomycin C.
Medication dosage is 1gm gemcitabine in 50cc phosphate-
buﬀered normal saline, then 40mg mitomycin C in 40cc
sterile water. The gemcitabine is instilled followed by the
mitomycin immediately afterward. We reported in 2006 on
a group of patients with treatment refractory non-muscle-
i n v a s i v eb l a d d e rc a n c e r( 8o f3 7h a du p p e rt r a c ti n v o l v e m e n t
[21]. Gemcitabine alone was eﬀective in only 1 of 14 patients
(7%) while sequential treatment with gemcitabine followed
by mitomycin was successful in 13 of 23 patients (57%).
The rationale for sequential treatment is that gemcitabine is
too acidic and aﬀects mitomycin activity if given together.
Additionally, gemcitabine primarily kills cells undergoing
DNA synthesis (S-phase) while mitomycin is non-cell phase-
speciﬁc and leads to cell cycle arrest. Gemcitabine is given
ﬁrstfollowedbymitomycintomaximizetherapeuticeﬃcacy.
8. Conclusions
Without large prospective or randomized data, the topical
treatment of upper tract urothelial cancer is to some extent
anecdotal. Topical treatment of upper tract urothelial cancer
has a role in selected patients, who must be committed to
close follow-up because of the risk of recurrence and more
concerning progression. The goal of treatment is to provide
noninvasive, nephron-sparing treatment without compro-
mising oncologic outcomes. Treatment can be successfully6 Advances in Urology
performed in the setting of a busy urologist’s oﬃce. Further
study is needed to identify the best candidates for this
treatment approach and to determine which agents and
schedule are most optimal. Our oﬃce-based approach to
upper tract urothelial carcinoma provides the clinician with
the framework to implement this treatment in practice.
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